Investor Relations
Living Cell Technologies is a fast-growing biotechnology company with a dual listing on the Australian Securities Exchange (ASX:LCT) and the international OTCQX (LVCLY). LCT has more than 1800 shareholders from Australasia, Europe and the US and is working to further strengthen its international shareholder base.
LCT is committed to clear and transparent communication with its investors and adheres strictly to corporate governance guidelines.
Investor Overview
Annual Reports
Download LCT’s 2009 Annual Report [6.24mb PDF]
Download LCT’s 2008 Annual Report [7.7mb PDF]
Download LCT’s 2007 Annual Report [3.14mb PDF]
Download LCT’s 2006 Annual Report [3.59mb PDF]
Download LCT’s 2005 Annual Report [3.8mb PDF]
Download LCT’s 2004 Annual Report [2.29mb PDF]
Corporate Governance
For more information on LCT’s stance on corporate governance, please click here.
OTCQX
For more information on the OTCQX and the purchase of American Depository Receipts (ADRs), click here.
Media Resources
To see LCT’s recent announcements, newsletters and investor-related information click here.
Search our site
Investor Information
Our Science
LCT’s patented encapsulation technology is a world first success.
More InformationManagement Team
LCT’s global team includes independent directors with extensive biotechnology, theraputics and capital raising experience.
More InformationDIABECELL®
Natural neo-natal porcine islets encapsulated in an alginate gel and transplanted for the treatment of insulin-dependent diabetes.
More Information